diagnostics – Verséa
 
HomeTag

diagnostics

Verséa Health, Inc. Announces the Official Launch of Party Safe™ Fentanyl ID Test – A Convenient and Accurate Solution for Fentanyl Detection On-the-Go

8/21/2024, Tampa, FL – Verséa Health, Inc. (“Verséa”), a Florida-based transformative healthcare company specializing in the commercialization of innovative diagnostics, therapeutics, and health services, has officially launched Party Safe™ Fentanyl ID Test. Manufactured by a leading US supplier to law enforcement and healthcare providers, Party Safe™ Fentanyl ID Test is a dependable over-the-counter product, featuring...

Verséa Holdings, Inc. is Launching Verséa Health and Verséa Easy Lab™ at the NACS Show 2022

At this year’s NACS Show 2022 Verséa Holdings, Inc. is launching their new business division Verséa Health and their Product Line Portfolio Verséa Easy Lab™. James Olin, Chief Commercial Officer at Verséa, explains the reason behind the launch: “Verséa Health was created with a mission to give millions of Americans direct-access to the most essential...

2 new COVID symptoms reported for BA.2 omicron variant

According to recent reports, the new BA.2 COVID-19 variant (a subvariant of the omicron variant called BA.1.) spreads more easily than the original omicron. Early data suggest that BA.2 is about 30% more transmissible than the original variant. The new BA.2 variant can also manifest different symptoms than the original strains. New symptoms include: Dizziness Fatigue...

Omicron variants – Statement from the WHO

Yesterday the WHO’s Technical Advisory Group on SARS-Cov-2 Virus Evolution (ATG-VE) published a statement on new omicron variants that have been circulating globally, accounting for nearly all sequences reported to GISAID: “Based on available data of transmission, severity, reinfection, diagnostics, therapeutics and impacts of vaccines, the group reinforced that the BA.2 sublineage should continue to...